OmniAb, Inc. (OABI) Q1 FY26 Earnings Call

Milestone-driven growth lifted Q1 revenue and guidance, while clinical advancement expands future royalty potential.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length47 minutes
EPS$-0.06
EPS consensus$-0.10
Revenue$14.4M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All OABI earnings ยท Back to OABI overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.